Other and unspecified metabolic disorders
Notes: AAT deficiency ; Dysplasminogenemia ; Hypoplasminogenemia ; Type 1 plasminogen deficiency ; Type 2 plasminogen deficiency ; Bisalbuminemia ; Lipodystrophy NOS ; Lipomatosis NOS ; Lipomatosis (Check) dolorosa [Dercum] ; Tumor lysis syndrome (spontaneous) ; Tumor lysis syndrome following antineoplastic drug chemotherapy ; Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes ; Myoclonic epilepsy associated with ragged-red fibers ; Dysmetabolic syndrome X ; Launois-Bensaude adenolipomatosis ; codes for associated conditions ; code for associated findings, such as: ; hydrocephalus (G91.4) ; otitis media (H67.-) ; respiratory disorder related to plasminogen deficiency (J99) ; code for adverse effect, if applicable, to identify drug (T45.1X5) ; codes for associated manifestations, such as: ; obesity (E66.-) ; histiocytosis X (chronic) (C96.6) ; monoclonal gammopathy (of undetermined significance) (D47.2) ; polyclonal hypergammaglobulinemia (D89.0) ; Waldenström macroglobulinemia (C88.0) ; Whipple’s disease (K90.81) ; disorders of pyruvate metabolism (E74.4) ; Kearns-Sayre syndrome (H49.81) ; Leber’s disease (H47.22) ; Leigh’s encephalopathy (G31.82) ; Mitochondrial myopathy, NEC (G71.3) ; Reye’s syndrome (G93.7) ; adult pulmonary Langerhans cell histiocytosis (J84.82) ; disorder of lipoprotein metabolism (E78.-)